Moberg Pharma

Moberg Pharma's mission is to commercialize proprietary pharmaceutical innovations by enhancing the delivery of established compounds, thereby reducing development risk and time-to-market. Its key achievement is the development and EU market approval of MOB-015, a novel topical treatment for onychomycosis now sold in Sweden and approved in 13 EU countries. The company's strategy focuses on leveraging its drug delivery platform to address high-unmet-need niches in dermatology, with a clear path toward commercialization and potential geographic expansion. Moberg operates as a lean, publicly-traded entity, utilizing capital markets to fund its focused growth initiatives.

Proprietary drug delivery platform focused on reformulating and optimizing the delivery of proven active pharmaceutical ingredients (APIs) to enhance efficacy, safety, and patient convenience, particularly for topical applications in dermatology.

MOB-015 competes in the prescription topical onychomycosis segment against products like Kerydin (tavaborole) and Jublia (efinaconazole), and more broadly against generic oral terbinafine. Its key differentiators are the proven potency of terbinafine and a formulation designed for superior nail penetration, aiming to offer best-in-class topical efficacy with an excellent safety profile.